Cullinan Therapeutics, Inc., a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced a new partnership with Genrix Bio. Under the agreement, Cullinan will pay an upfront license fee of $20 million for exclusive global rights, excluding Greater China, to develop and commercialize velinotamig, a BCMAxCD3 bispecific T cell engager. This collaboration aims to advance Cullinan's leadership in T cell engager development for autoimmune diseases, adding to their pipeline that already includes a CD19 TCE. Genrix Bio stands to receive up to $292 million in development and regulatory milestones, an additional $400 million in sales-based milestones, and tiered royalties from mid-single digits to mid-teens on potential net sales outside Greater China. Cullinan's strengthened portfolio positions them to address a broader range of diseases while maintaining financial resources into 2028.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。